Early-stage biotech exits stealth mode with $5.3M funding boost

04/5/2013 | MedCityNews.com

Calif.-based Nurix has emerged from its stealth period with $5.3 million in equity funding from four investors, according to a securities filing. The biotech startup seeks to develop T-cell-specific immunosuppressant drugs for autoimmune diseases.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ